543500 Stock Overview
Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Evoq Remedies Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹9.18 |
52 Week High | ₹19.44 |
52 Week Low | ₹8.90 |
Beta | 0 |
1 Month Change | -29.44% |
3 Month Change | -37.76% |
1 Year Change | -38.60% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -61.35% |
Recent News & Updates
Recent updates
Shareholder Returns
543500 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -6.3% | 2.7% | 2.5% |
1Y | -38.6% | 63.9% | 47.3% |
Return vs Industry: 543500 underperformed the Indian Pharmaceuticals industry which returned 65% over the past year.
Return vs Market: 543500 underperformed the Indian Market which returned 48.6% over the past year.
Price Volatility
543500 volatility | |
---|---|
543500 Average Weekly Movement | 11.3% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 543500's share price has been volatile over the past 3 months.
Volatility Over Time: 543500's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | n/a | https://www.evoqremedies.com |
Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India. The company trades in sweeteners, such as acesulfame potassium, aspartem, dextrose, erythritol, euro vanillin powder, malodextrin, miglitol, neotame, pharma sugar; amino acids, such as L- alanine, L-arginine, L-aspartic acid, L-carnitine, L-cystine, L-glutamic acids, L-glutamine, L-glutathione, L-glycine, L-isoleucine, L-lavine, L-leucine, L-ornathene, L-aspartate, L-phenylamine, L-serine, L-threonine, L-trytophan, L-tyrosine, L-lysine, N-acetyl, and L-andystine; excipients, which include aspartem, bronopol, cross carmellous sodium, cross povidone, ethyl olliate, hard peraffin, hpmc all grades, light liquid paraffin, mannitol, menthol crystal, etc.; neutraceuticals, such as alpha lipoic acid, astaxanthin, bacopa benfothiamine, betacarotene, biotin, bonistein, bovine colostrum powder, etc.; and opthalamics, which include atropine sulphate, bimatoprost, brimonidine, bromfenac, cyclopentolate, dorzolamide fluoromethelone, flurbiprofen, gatifloxacin, ketorolac tromethamine, latanoprost, loteprednol etabonate, moxifloxacin, natamycin, nepafenac, olopatadine, sulphacetamide sodium, timolol meleate, etc. It also offers ointments, such as adapalene, allantoin, avobenzone, azealic acid beclomethasone di propionate, betamethasone and salts, calamine, chlorocresol, citrimide clindamycin phoshphate, clobetasol propionate, clotrimazole, cyclosporine, fluocinolol acetonide, fusidic acid, gamabenzene, gentamycin sulphate, halobetasol, hydroquinone, etc.; and oncology drugs, such as abiraterone acetate, alfuzosin, anastrazole, axitinib azacitidine, bicalutamide, bleomycin, bosutinib, busualphan cabazitaxel amphorous, capcitabine, carboplatin, cisplatin, etc. In addition, the company offers vitamins, dairy and spice products, sterile, active pharmaceutical ingredients, and veterinary feed products. The company was incorporated in 2010 and is based in Ahmedabad, India.
Evoq Remedies Limited Fundamentals Summary
543500 fundamental statistics | |
---|---|
Market cap | ₹124.85m |
Earnings (TTM) | ₹13.63m |
Revenue (TTM) | ₹145.25m |
9.2x
P/E Ratio0.9x
P/S RatioIs 543500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
543500 income statement (TTM) | |
---|---|
Revenue | ₹145.25m |
Cost of Revenue | ₹65.29m |
Gross Profit | ₹79.96m |
Other Expenses | ₹66.33m |
Earnings | ₹13.63m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.00 |
Gross Margin | 55.05% |
Net Profit Margin | 9.39% |
Debt/Equity Ratio | 5.1% |
How did 543500 perform over the long term?
See historical performance and comparison